By targeting and inhibiting IDO1 and decreasing kynurenine, BMS-986205 is able to determine a reduction in tumor-associated regulatory T cells (Tregs) and to restore and promote the activation and proliferation of several immune cells, such as natural killer cells, dendritic cells, and T lymphocytes cells. The gene discussed is IDO1; the disease is neoplasm.